跳至主要内容
临床试验/CTIS2022-501250-12-01
CTIS2022-501250-12-01招募中1 期

SPVN06-CLIN-01

Sparingvision0 个研究点目标入组 33 人开始时间: 2022年12月16日最近更新:

试验速览

阶段
1 期
状态
招募中
发起方
Sparingvision
入组人数
33

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Sparingvision

相似试验

招募中
1 期
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.Solid tumors, Non-Small Cell Lung Cancer, Cervical Cancer, Endometrial CancerMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104
CTIS2024-511744-27-00Cullinan Mica Corp.500
进行中(未招募)
1 期
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumorsgastroesophageal junction [GEJ] carcinoma, Non-small cell lung cancer (NSCLC), Gastric cancer, Cervical cancer, Ovarian cancer, Endometrial cancer, Malignant ovarian GCT with the exception of pure teratomas, Malignant testicular germ cell tumor (GCT) with the exception of pure teratomas, Gastroesophageal junction carcinoma, Malignant extragonadal GCT with the exception of pure teratomas or tumors with primaries arising from the central nervous system (CNS)MedDRA version: 21.1Level: LLTClassification code: 10043338Term: Testicular malignant germ cell tumor NOS Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: HLTClassification code: 10033222Term: Ovarian germ cell neoplasms malignant Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10066354Term: Adenocarcinoma of the gastroesophageal junction Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10073060Term: Extragonadal primary germ cell tumor Class: 10029104
CTIS2022-500094-14-00Seagen Inc.254
招募中
1 期
Study of SGN-PDL1V in Advanced Solid Tumors
CTIS2023-506604-18-00Seagen Inc.322
招募中
1 期
A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in PNH Patients with a Sub-optimal Response to the C5 inhibitor, Ravulizumab
CTIS2022-501190-39-01Omeros Ireland Limited14
进行中(未招募)
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular disease
CTIS2024-510878-24-00Cereno Scientific AB48